Author:
Nishio Makoto,Hida Toyoaki,Atagi Shinji,Sakai Hiroshi,Nakagawa Kazuhiko,Takahashi Toshiaki,Nogami Naoyuki,Saka Hideo,Takenoyama Mitsuhiro,Maemondo Makoto,Ohe Yuichiro,Nokihara Hiroshi,Hirashima Tomonori,Tanaka Hiroshi,Fujita Shiro,Takeda Koji,Goto Koichi,Satouchi Miyako,Isobe Hiroshi,Minato Koichi,Sumiyoshi Naoki,Tamura Tomohide
Reference19 articles.
1. Cancer Information Service NCC, Japan. Cancer registry and statistics [in Japanese]. Secondary Cancer registry and statistics [in Japanese]. 2015. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei14/dl/11_h7.pdf (accessed 28 Jul 2016).
2. Cancer Information Service NCC, Japan. Cancer registry and statistics [in Japanese]. Secondary Cancer registry and statistics [in Japanese]. 2016. http://ganjoho.jp/data/reg_stat/statistics/dl/cancer_incidence(1975-2012).xls (accessed 28 Jul 2016).
3. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma;Travis;J Thorac Oncol,2011
4. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy;Krzakowski;J Clin Oncol,2010
5. A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer;Pallis;BMC Cancer,2010
Cited by
63 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献